GE91.F GENMAB AS SP.ADR/1/10DK 1

Healthcare Biotechnology Frankfurt Exchange
48.40 EUR
Close of Nov 12, 2026
20.20 51.50
Market cap
EUR 29.8B
P/E
47.9x
P/B
5.24x
ROE
14.7%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is GE91.F undervalued?

Graham number

The Graham number of GENMAB AS SP.ADR/1/10DK 1 cannot be estimated reliably (the estimate is too far from the market price).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

GENMAB AS SP.ADR/1/10DK 1 fundamental analysis

No fundamental analysis for GENMAB AS SP.ADR/1/10DK 1 yet.

GENMAB AS SP.ADR/1/10DK 1 stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About GENMAB AS SP.ADR/1/10DK 1

Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also develop…

Full company profile